Table 1.
Characteristics of patients with brainstem metastases
| Characteristic | Value |
|---|---|
|
Patients (F/M), n |
36, (17/19) |
|
Lesions, n |
38 |
|
Median age (range), y |
62 (28-89) |
|
Primary Malignancy, n (%) |
|
| Lung |
14 (39%) |
| Breast |
7 (19%) |
| Colon |
4 (11%) |
| Other |
11 (31%) |
|
Symptoms, n (%) |
25 (39%) |
| Headache |
8 (22%) |
| Weakness |
6 (17%) |
| Ataxia |
7 (19%) |
| Visual Changes |
6 (17%) |
|
Median KPS score (range) |
80 (60-90) |
|
Median GPA score (range) |
1.5 (0-3.5) |
|
RPA class, n (%) |
|
| I |
4 (11%) |
| II |
30 (83%) |
| III |
2 (6%) |
|
Number of intracranial metastases at time of SRS, n (%) |
|
| 1 |
9 (24%) |
| 2 to 4 |
23 (61%) |
| >4 |
6 (16%) |
|
Median interval between primary diagnosis and SRS (range), mo |
16 (1-190) |
|
Median tumor volume (cc), range |
0.94 (0.01-4.2) |
|
Location of treated brainstem metastasis, n (%) |
|
| Midbrain |
11 (29%) |
| Pons |
25 (66%) |
| Medulla |
2 (5%) |
|
WBRT for brain metastases before SRS, n (%) |
18 (47%) |
|
Median SRS dose (range), Gy |
17 (12-24) |
|
Treatment Fractions, n (%) |
|
| 1 |
20 (56%) |
| 2 |
2 (6%) |
| 3 |
13 (36%) |
| 5 |
1 (3%) |
|
Treatment Modality, n (%) |
|
| Cyberknife |
34 (89%) |
| Trilogy | 4 (11%) |